Pharmacokinetic and pharmacodynamic considerations of cephalosporin use in children

Manon Tauzin1, Naim Ouldali2,3,4, Stéphane Béchet2

  • 1Neonatal Intensive Care Unit, Centre Hospitalier Intercommunal de Créteil, Créteil, France.

Insights

Optimizing cephalosporin use in children requires understanding their pharmacokinetics and in vitro activity. Careful dosing based on time above minimal inhibitory concentration (fT>MIC) can improve efficacy and combat emerging resistance.

Area of Science:

  • Pharmacology and Microbiology
  • Pediatric Infectious Diseases

Background:

  • Cephalosporins are widely used in children due to their efficacy and safety.
  • Pediatric pharmacokinetics of cephalosporins exhibit significant inter-individual variability.
  • Widespread cephalosporin use contributes to the rise of Enterobacteriaceae producing broad-spectrum beta-lactamases.

Purpose of the Study:

  • To review in vitro activities and pharmacokinetic characteristics of cephalosporins in pediatric populations.
  • To propose using estimated time above minimal inhibitory concentration (fT>MIC) for optimizing cephalosporin dosing.
  • To discuss clinical use, emerging resistance, and future strategies for cephalosporin therapy.

Main Methods:

  • Review of in vitro antimicrobial activities of cephalosporins.
  • Analysis of pharmacokinetic data in pediatric patients.
  • Estimation of pharmacokinetic/pharmacodynamic targets (fT>MIC) for various cephalosporins.

Main Results:

  • Cephalosporins display heterogeneous in vitro activity and pharmacokinetic profiles in children.
  • Inter-individual pharmacokinetic variability is substantial due to maturational changes.
  • Emergence of resistance is linked to the broad use of these antibiotics.

Conclusions:

  • Clinicians must understand cephalosporin pharmacokinetics and activity to optimize pediatric use.
  • Restricting broad-spectrum use is crucial to mitigate the emergence of resistant strains.
  • Development of new agents or combinations is needed to address resistance challenges.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
184
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
227
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
210
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
163
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
224
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.8K